Navigation Links
Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Date:8/19/2007

LEXINGTON, Mass., Aug. 17 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for VALSTAR(R). VALSTAR, a sterile solution of valrubicin for intravesical instillation, is the only product approved by the FDA for therapy of bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder.

VALSTAR was removed from the market in 2002 due to impurities in the original formulation and was placed on the FDA Drug Shortages List. Indevus solved the impurity issue and submitted a chemistry, manufacturing and controls (CMC) NDA supplement to the FDA in May 2007. The FDA approvable letter was in response to this chemistry supplement.

In the approvable letter, the FDA asked for clarification regarding manufacturing validation protocols and for additional data on the manufacturing process.

"VALSTAR offers an effective alternative for bladder cancer patients who have failed BCG therapy and are not candidates for immediate cystectomy," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The FDA requests in the approvable letter are easily addressable with existing data and the completion of a few brief process related investigations. We expect to supply the FDA with a complete response within the next two months. We remain on track for a late 2007 or early 2008 re- introduction."

About VALSTAR(R)

VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.

In clinical tria
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
(Date:5/5/2015)... Mich. (PRWEB) May 05, 2015 ... publishing services to develop custom course materials for smaller ... annual enrollments as low as 200 students. , ... a broader range of higher education instructors,” said Jeff ... the country, we can do our part to make ...
(Date:5/5/2015)... May 5, 2015  Renova™ Therapeutics, a biopharmaceutical ... failure and other chronic diseases, has engaged RAND ... designed to reflect the healthcare patterns of multiple ... will be used to characterize the impact the ... on those groups of patients and the overall ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Franz Inc ... technology, today announced that its flagship product, AllegroGraph, has been ... Graph Database Market Update report. AllegroGraph is a ... the W3C industry standards. Graph databases are skyrocketing in popularity ... according to a recent DBMS ranking by DB-Engines. ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, today,reported results for the three months ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), For fiscal year ... 2006. For the year ended December 31, 2007, ...
... 1:30 p.m. (Pacific); ... http://www.adventrx.com , SAN DIEGO, March 6 ADVENTRX Pharmaceuticals,Inc. (Amex: ... call and,webcast on Thursday, March 13th, 2008 at 1:30 p.m. Pacific ... results. Evan M.,Levine, chief executive officer and president of ADVENTRX, will ...
... March 6, 2008--Researchers at the Gladstone Institute of Cardiovascular ... have identified for the first time how tiny genetic ... embryonic stem (ES) cells into cardiac muscle. As reported ... lab of GICD Director, Deepak Srivastava, MD, demonstrated that ...
Cached Biology Technology:EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 2EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 3EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 4EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 5Gladstone scientists identify role of tiny RNAs in controlling stem cell fate 2
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... 2012) -- Scientists at Weill Cornell Medical College have ... -- exerts a spigot-like function, controlling the volume of ... of brain neurons. The study, published online in ... other through these signals, relaying thoughts, feelings and action, ...
... between an ant species and a carnivorous plant, the ants ... host-plant and provide significant amounts of nutrients derived from their ... research published May 9 in the open access journal ... Nepenthes bicalcarata grows in the nutrient-poor peatswamp forests ...
... genetics versus historical records diverge greatly, making it difficult ... commercial whaling of the 19th and early 20th centuries, ... prehistoric gray whales supports the idea that the population ... decrease that is consistent with whaling as the cause. ...
Cached Biology News:New study discovers powerful function of single protein that controls neurotransmission 2New study discovers powerful function of single protein that controls neurotransmission 3New study discovers powerful function of single protein that controls neurotransmission 4Whale population size, dynamics determined based on ancient DNA 2
Request Info...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
TCP-1 alpha (H-110)...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: